TradeLink Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

TradeLink Capital’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-3,400	Closed	-$36K	–	340
2014 Q1	$36K	Buy	+3,400	New	+$36.2K	0.05%	193

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

TradeLink Capital's BCRX Position: Q2 2014 in Review

TradeLink Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2014, closing a stake of 3,400 shares — an estimated $36K sold.

TradeLink Capital first reported a position in BCRX in Q1 2014 and held it in 1 quarter. The position peaked at $36K in Q1 2014. 103 funds tracked by Wall St. Rank hold BCRX as of Q2 2014.

TradeLink Capital reported no remaining BioCryst Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
TradeLink Capital sold 3,400 BioCryst Pharmaceuticals shares in Q2 2014, an estimated $36K.
TradeLink Capital first reported a position in BioCryst Pharmaceuticals in Q1 2014 and held it in 1 quarter.
TradeLink Capital's BioCryst Pharmaceuticals position peaked at $36K in Q1 2014.
103 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2014.

Based on TradeLink Capital's 13F filing for Q2 2014, filed 31 Jul 2014.